On this subject, an excellent piece in todayâ€™s on-line edition of The Journal of Life Sciences. Itâ€™s titled, â€œNo Silver Bulletâ€ and points out that, just because we do not, as of yet, have a cure for Alzheimerâ€™s Disease, does not mean that our increased and enhanced ability to diagnonse this scourge isnâ€™t a significant leap forward.
Hereâ€™s a link to the article:
The author, April Lynch, is a staff writer at the San Jose Mercury News, focusing on health, medicine, biotech, genomics, and environmental investigations. She has also worked as the paperâ€™s editor for science and health coverage. She is the author of a forthcoming book on genomic medicine
According to Lynch:
â€œBefore people develop full-blown Alzheimerâ€™s disease, they usually experience a condition called mild cognitive impairment, or MCI. The signs of MCI, such as minor memory loss, can be so subtle that many people miss them, or dismiss them as routine â€œsenior momentsâ€ that come with aging. Alzheimerâ€™s researchers say that A-beta deposits and damage are already well underway in these peoplesâ€™ brains. If more of them could be caught early, and the new drugs work at limiting brain destruction, doctors could start therapy before serious illness sets in.â€
For those following the War Againist Alzheimers, you may also want to read the recent CMPI report on the potential economic impact that new treatments for Alzheimer's disease could have on the U.S. economy. The study was sponsored by ACT-AD, a coalition of 49 national organizations seeking to accelerate development of potential cures and treatments for Alzheimerâ€™s disease. The full report can be found here:
The fight against Alzheimerâ€™s Disease is another clarion call for the expeditious pursuit of the Critical Path Initiative.